Current Report Filing (8-k)
November 28 2018 - 6:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 28, 2018
DexCom, Inc.
(Exact
Name of the Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware
|
|
000-51222
|
|
33-0857544
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
6340 Sequence Drive, San Diego, CA
|
|
|
|
92121
|
(Address of Principal Executive Offices)
|
|
|
|
(Zip Code)
|
(858)
200-0200
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, If Changed Since Last Report)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 8.01 Other Events.
On November 28, 2018, DexCom, Inc. (
DexCom
) issued a press release announcing the pricing of its offering of $750 million
aggregate principal amount of 0.75% Convertible Senior Notes due 2023 (the
Notes
) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. DexCom also
granted the initial purchasers of the Notes a
13-day
option to purchase up to an additional $100 million aggregate principal amount of Notes. A copy of the press release announcing the pricing of the
Notes is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
Dated: November 28, 2018
|
|
|
|
DEXCOM, INC.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ P
ATRICK
M
URPHY
|
|
|
|
|
Name:
|
|
Patrick Murphy
|
|
|
|
|
Title:
|
|
Senior Vice President, General Counsel and Chief Compliance Officer
|
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Apr 2024 to May 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From May 2023 to May 2024